Matrix-M

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Matrix-M
Accession Number
DB16369
Description

Matrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax.1 This compound is administered alongside vaccines to enhance biological functions: creating robust and long-lasting immune responses that may allow for dose-sparing of vaccines.

Type
Biotech
Groups
Investigational
Synonyms
  • Matrix-M1
  • Matrix-M1 Adjuvant
External IDs
  • Matrix-M

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action

Matrix-M can enhance activated T-cell, B-cell, and antigen-presenting cell populations by inducing the influx of antigen-presenting cells.1 It can also enhance both B-cell immunity and T-cell immunity.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Novavax: Novavax addresses urgent global public health needs with innovative technology [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingPreventionCoronavirus (SARS-CoV) / Coronavirus Disease 2019 (COVID‑19)1
2CompletedPreventionRespiratory Syncytial Virus (RSV)1
2Not Yet RecruitingTreatmentMalaria caused by Plasmodium falciparum1
2RecruitingPreventionCoronavirus Disease 2019 (COVID‑19)1
1CompletedPreventionEbola1
1CompletedPreventionMatrix M / Plasmodium Infections1
1CompletedPreventionPlasmodium Infections1
1Not Yet RecruitingPreventionMalaria caused by Plasmodium falciparum1
1Not Yet RecruitingTreatmentMalaria caused by Plasmodium falciparum1
1TerminatedPreventionMalaria caused by Plasmodium falciparum1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 19, 2020 20:30 / Updated on December 19, 2020 20:42

Th 2